PE20201344A1 - Vacunas terapeuticas anti-abeta - Google Patents

Vacunas terapeuticas anti-abeta

Info

Publication number
PE20201344A1
PE20201344A1 PE2020001520A PE2020001520A PE20201344A1 PE 20201344 A1 PE20201344 A1 PE 20201344A1 PE 2020001520 A PE2020001520 A PE 2020001520A PE 2020001520 A PE2020001520 A PE 2020001520A PE 20201344 A1 PE20201344 A1 PE 20201344A1
Authority
PE
Peru
Prior art keywords
liposome
vaccine composition
abeta
vaccine compositions
presented
Prior art date
Application number
PE2020001520A
Other languages
English (en)
Inventor
Emma Fiorini
Verhille Marija Vukicevic
Bosch Maria Pihlgren
Original Assignee
Ac Immune Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ac Immune Sa filed Critical Ac Immune Sa
Publication of PE20201344A1 publication Critical patent/PE20201344A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0007—Nervous system antigens; Prions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0003—Invertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/05—Actinobacteria, e.g. Actinomyces, Streptomyces, Nocardia, Bifidobacterium, Gardnerella, Corynebacterium; Propionibacterium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • C12N9/1077—Pentosyltransferases (2.4.2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
    • A61K2039/645—Dendrimers; Multiple antigen peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16211—Lymphocryptovirus, e.g. human herpesvirus 4, Epstein-Barr Virus
    • C12N2710/16232—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16211—Lymphocryptovirus, e.g. human herpesvirus 4, Epstein-Barr Virus
    • C12N2710/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16033—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Dispersion Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

Composicion de vacuna liposomal que comprende un antigeno peptidico para celulas B derivado de amiloide beta (Abeta) presentado en la superficie del liposoma. La composicion de vacuna tambien comprende un peptido que comprende un epitopo para celulas T universal encapsulado en el liposoma. La composicion de vacuna tambien comprende un coadyuvante, que puede formar parte del liposoma y puede estar presentado al menos en parte en su superficie. Estas composiciones de vacunas se usan para tratar, prevenir, inducir una respuesta inmune protectora o aliviar los sintomas de una enfermedad o una afeccion asociada a amiloide beta o una afeccion caracterizada o asociada a la perdida de capacidad de memoria cognitiva en un sujeto. Las composiciones de vacunas pueden proveerse como kits. Metodos relacionados para producir composiciones de vacunas liposomales
PE2020001520A 2018-04-10 2019-04-09 Vacunas terapeuticas anti-abeta PE20201344A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18166659 2018-04-10
EP18202366 2018-10-24
PCT/EP2019/058980 WO2019197414A1 (en) 2018-04-10 2019-04-09 Anti-abeta therapeutic vaccines

Publications (1)

Publication Number Publication Date
PE20201344A1 true PE20201344A1 (es) 2020-11-25

Family

ID=66092353

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2020001520A PE20201344A1 (es) 2018-04-10 2019-04-09 Vacunas terapeuticas anti-abeta

Country Status (18)

Country Link
US (2) US10828351B2 (es)
EP (1) EP3773712A1 (es)
JP (1) JP2021521149A (es)
KR (1) KR20200143422A (es)
AU (1) AU2019253193A1 (es)
BR (1) BR112020020660A2 (es)
CA (1) CA3095983A1 (es)
CL (1) CL2020002586A1 (es)
CO (1) CO2020013977A2 (es)
CR (1) CR20200533A (es)
IL (1) IL277851A (es)
MA (1) MA52180A (es)
MX (1) MX2020010621A (es)
PE (1) PE20201344A1 (es)
PH (1) PH12020551670A1 (es)
SG (1) SG11202009917PA (es)
TW (1) TW202003031A (es)
WO (1) WO2019197414A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112020020660A2 (pt) * 2018-04-10 2021-03-02 Ac Immune Sa vacinas terapêuticas anti-abeta
WO2023152260A1 (en) * 2022-02-09 2023-08-17 Ac Immune Sa Anti-alpha-synuclein therapeutic vaccines

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ME00183B (me) 2000-02-21 2011-02-10 Pharmexa As Novi postupak za deregulaciju amiloida
AU2002233166B2 (en) 2001-02-19 2006-06-29 Pharmexa A/S Synthetic vaccines comprising polyhydroxypolymer carriers
MY144532A (en) 2001-08-20 2011-09-30 Lundbeck & Co As H Novel method for down-regulation of amyloid
US20040091945A1 (en) 2002-07-17 2004-05-13 Cheryl Fitzer-Attas Peptides and methods of screening immunogenic peptide vaccines against Alzheimer's Disease
US20060276400A1 (en) * 2005-06-06 2006-12-07 Hedy Adari Modulation of cholesteryl ester transfer protein (CETP) activity
CA2633399C (en) * 2005-12-12 2016-01-26 Ac Immune S.A. Therapeutic vaccine
KR20080103560A (ko) 2006-02-22 2008-11-27 가부시끼가이샤 하야시바라 세이부쓰 가가꾸 겐꾸조 항 아밀로이드-β-펩티드 항체 생산 유도용 펩티드 백신
US8560338B2 (en) * 2006-03-01 2013-10-15 Tag, Llc Method for competitive prescription drug and/or bidding service provider selection
EA026787B1 (ru) 2007-08-27 2017-05-31 Общество С Ограниченной Ответственностью "Ниармедик Плюс" Конструкция нуклеиновой кислоты и ее применение для лечения, предотвращения и сдерживания болезни альцгеймера
WO2009090650A2 (en) 2008-01-16 2009-07-23 Ben-Gurion University Of The Negev Research And Development Authority Vaccine for alzheimer's disease
EP2296696B1 (en) * 2008-06-05 2014-08-27 ImmunoVaccine Technologies Inc. Compositions comprising liposomes, an antigen, a polynucleotide and a carrier comprising a continuous phase of a hydrophobic substance
US9498522B2 (en) 2008-08-07 2016-11-22 Mercia Pharma Inc. Immunotherapeutic compositions for the treatment of alzheimer'S disease
BR112012003977A2 (pt) 2009-08-26 2017-06-06 Selecta Biosciences Inc composições que induzem ajuda de célula t
EP2547364B1 (en) 2010-03-15 2016-12-14 Academisch Ziekenhuis Leiden h.o.d.n. LUMC Peptides, conjugates and method for increasing immunogenicity of a vaccine
US9289488B2 (en) 2010-08-12 2016-03-22 Ac Immune Sa Vaccine engineering
WO2012055933A1 (en) * 2010-10-26 2012-05-03 Ac Immune S.A. Liposome-based construct comprising a peptide modified through hydrophobic moieties
SG11201401177WA (en) 2011-10-06 2014-04-28 Immunovaccine Technologies Inc Liposome compositions comprising an adjuvant that activates or increases the activity of tlr2 and uses thereof
US9102752B2 (en) 2013-03-15 2015-08-11 United Biomedical, Inc. Peptide vaccine for prevention and immunotherapy of dementia of the Alzheimer's type
MA40824A (fr) 2014-10-22 2017-08-29 Saiba Gmbh Particules de cmv de type virus modifié
CN105418767B (zh) 2015-12-22 2019-03-08 云南大学 一种用于制备Aβ表位疫苗的融合蛋白及其制备方法和用途
BR112020020660A2 (pt) * 2018-04-10 2021-03-02 Ac Immune Sa vacinas terapêuticas anti-abeta

Also Published As

Publication number Publication date
WO2019197414A1 (en) 2019-10-17
US12005102B2 (en) 2024-06-11
CO2020013977A2 (es) 2021-01-29
TW202003031A (zh) 2020-01-16
US10828351B2 (en) 2020-11-10
EP3773712A1 (en) 2021-02-17
JP2021521149A (ja) 2021-08-26
CR20200533A (es) 2021-02-22
PH12020551670A1 (en) 2021-06-07
KR20200143422A (ko) 2020-12-23
SG11202009917PA (en) 2020-11-27
CL2020002586A1 (es) 2021-01-15
MX2020010621A (es) 2020-10-20
CA3095983A1 (en) 2019-10-17
BR112020020660A2 (pt) 2021-03-02
US20190307867A1 (en) 2019-10-10
MA52180A (fr) 2021-02-17
AU2019253193A1 (en) 2020-11-26
US20210093700A1 (en) 2021-04-01
IL277851A (en) 2020-11-30

Similar Documents

Publication Publication Date Title
CL2019002922A1 (es) Anticuerpos anti-péptido beta amiloide n3pglu y sus usos.
CO2020013977A2 (es) Vacunas terapeuticas anti-abeta
AR105470A1 (es) Métodos para inducir una respuesta inmune
AR107078A1 (es) Anticuerpo antimiostatina, polipéptidos que contienen regiones fc variantes así como métodos de uso
AR098256A1 (es) Vectores para expresión de antígenos asociados a próstata
CL2021000142A1 (es) Receptores antigénicos quiméricos con especificidad para bcma y usos de estos.
CR20170326A (es) Anticuerpos antimiostatina, polipéptidos que contienen regiones fc variantes, y métodos de uso
PE20210323A1 (es) Proteinas de fusion que comprenden progranulina
CO2020014217A2 (es) Moduladores de enzimas modificadoras de metilo, composiciones y usos de estos
CL2018003510A1 (es) Anticuerpos antagonistas que se unen en forma de t a tgfb1, tgfb2 y tgfb3 humano, y su uso en el tratamiento de fibrosis pulmonar.
CL2017002237A1 (es) Proteína de unión de il-18 (il-18bp) y anticuerpos en enfermedades inflamatorias.
CL2015002941A1 (es) Usos terapéuticos de empaglifozina
CO6670526A2 (es) Anticuerpos peptídicos beta amiloide anti-n3p glu y usos de los mismos
UY32812A (es) Anticuerpos humanos de alta afinidad para angiopoyetina -2 humana.
BR112015009070A2 (pt) proteína de fusão ou coquetel de antígenos; uso de uma proteína de fusão ou um coquetel de antígenos; vacina; e método para imunizar um animal, que inclui um ser humano, contra tuberculose causada por microbactérias virulentas
DOP2024000040A (es) Vacunas para vhb y métodos de tratamiento de vhb
CO2018002483A2 (es) Ciano tienotriazolpirazinas y usos de las mismas
CR20190480A (es) Uso de antagonistas de klk5 para el tratamiento de una enfermedad
CO2021010786A2 (es) Toxinas apxia, apxiia y apxiiia inactivadas
CO2017001614A2 (es) Vacuna en vector recombinante de adenovirus aviar serotipo 9
CL2021002582A1 (es) Vacunas contra el circovirus porcino tipo 3 (pcv3), su producción y usos
CL2018000513A1 (es) Vacunas de pestivirus para temblores congénitos
MX2016001695A (es) Composiciones inmunogenas de combinacion.
AR114761A1 (es) VACUNAS TERAPÉUTICAS ANTI-Ab
EA202092403A1 (ru) Терапевтические вакцины против бета-амилоида